NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

I agree flipper44. In fact, I would like to hear your opinions on what I believe.

I believe that what makes the DCVax vaccine platform, both DCVax-L and DCVax Direct, a tumor and tissue agnostic treatment is its Mechanism of Action (MOA), as displayed on slides 5,6,7 and 8.

It appears that the DCVax vaccine platform will be effective in treating all or most solid tumor cancers, including: colon, lung, pancreatic, ovarian, breast, prostate, etc., because of its MOA of getting each patients dendritic cells to send more T-cells to the tumor(s) sites to fight and destroy the cancer tumor(s) regardless of which organ(s) the cancer tumor is located in.

I do not believe that the DCVax vaccine is tissue agnostic because it targets specific biomarkers, or because its only effective in patients with certain gene types (methylated, mesenchymal, etc.). Although, presently as a mono-therapy, it is more effective in certain gene types than other gene types. But, it seems to extend overall survival (OS) for all gene types.

Also, in combination with other approved treatments, such as: poly-ICLC, PD-1 inhibitors, CSF1R inhibitors,etc., it can extend OS even more for all gene types. And it will effectively cure a significantly higher percentage cancer patients